Evidence map›Paper›PMID 25198066›Full record

ArticlePloS one2014

Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.

Matthew Wortham, Changcun Guo, Monica Zhang, Lingyun Song, Bum-Kyu Lee, Vishwanath R Iyer, Terrence S Furey, Gregory E Crawford, Hai Yan, Yiping He

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Matthew WorthamDepartment of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America.
Changcun GuoDepartment of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America.
Monica ZhangDepartment of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America.
Lingyun SongDuke Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, United States of America.
Bum-Kyu LeeDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, United States of America.
Vishwanath R IyerDepartment of Molecular Biosciences, University of Texas at Austin, Austin, Texas, United States of America.
Terrence S FureyDepartment of Genetics, Department of Biology, Carolina Center for Genome Sciences, and Lineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Gregory E CrawfordDuke Center for Genomic and Computational Biology, Duke University, Durham, North Carolina, United States of America; Department of Pediatrics, Division of Medical Genetics, Duke University Medical Center, Durham, North Carolina, United States of America.
Hai YanDepartment of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America.
Yiping HeDepartment of Pathology, The Pediatric Brain Tumor Foundation Institute, and The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina, United States of America.
Pediatric Brain Tumor Foundation · USDuke University · USThe University of Texas at Austin · USDuke Medical Center · USDuke University Hospital · USUniversity of North Carolina at Chapel Hill · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8M
Comprehensive Identification of Active Functional Elements in Human ChromatinU54HG004563 · NHGRI · DUKE UNIVERSITY · PI CRAWFORD, GREGORY E · 2007 to 2011
$9.7M
Gene regulatory networks during the transition from quiescence to proliferationR01CA130075 · NCI · UNIVERSITY OF TEXAS AT AUSTIN · PI IYER, VISHWANATH R · 2008 to 2012
$1.2M
The Role of OTX2 in Molecular Pathogenesis of MedulloblastomaR01CA118822 · NCI · DUKE UNIVERSITY · PI YAN, HAI · 2006 to 2010
$1.2M
NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA118822NCI NIH HHS R01CA118822NCI NIH HHS R01 CA130075NCI NIH HHS R01CA130075NHGRI NIH HHS U54 HG004563NHGRI NIH HHS U54HG004563PHS HHS RP120194
6 · The paper itself

Abstract

Despite an emerging understanding of the genetic alterations giving rise to various tumors, the mechanisms whereby most oncogenes are overexpressed remain unclear. Here we have utilized an integrated approach of genomewide regulatory element mapping via DNase-seq followed by conventional reporter assays and transcription factor binding site discovery to characterize the transcriptional regulation of the medulloblastoma oncogene Orthodenticle Homeobox 2 (OTX2). Through these studies we have revealed that OTX2 is differentially regulated in medulloblastoma at the level of chromatin accessibility, which is in part mediated by DNA methylation. In cell lines exhibiting chromatin accessibility of OTX2 regulatory regions, we found that autoregulation maintains OTX2 expression. Comparison of medulloblastoma regulatory elements with those of the developing brain reveals that these tumors engage a developmental regulatory program to drive OTX2 transcription. Finally, we have identified a transcriptional regulatory element mediating retinoid-induced OTX2 repression in these tumors. This work characterizes for the first time the mechanisms of OTX2 overexpression in medulloblastoma. Furthermore, this study establishes proof of principle for applying ENCODE datasets towards the characterization of upstream trans-acting factors mediating expression of individual genes.

Indexed as

Cerebellar NeoplasmsChromatinChromatin ImmunoprecipitationChromosome StructuresDNA MethylationGene Expression Regulation, NeoplasticHumansMedulloblastomaOtx Transcription FactorsPromoter Regions, GeneticRegulatory Elements, TranscriptionalRetinoidsTrans-ActivatorsTumor Cells, CulturedChromatinOTX2 protein, humanOtx Transcription FactorsRetinoidsTrans-Activators

Identifiers

PMID25198066
PMCPMC4157845
OpenAlexW2123615367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.